Among the industry-sponsored clinical trials initiated in Q1 2017, oncology trials dominated the field, followed by clinical trials for CNS.

Figure 1: oncology dominates industry-sponsored clinical trials in Q1 2017

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Source: GlobalData, Pharma Intelligence Center, Clinical Trials Database [Accessed April 30, 2017]

Among these studies, there are more Phase I (241) studies than Phase II (234) and Phase III (193), accounting for 29%, 28% and 23% of the total clinical trials, respectively.

See Also:

Figure 2: industry-sponsored clinical trials initiated in Q1 2017 by phase 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Source: GlobalData, Pharma Intelligence Center, Clinical Trials Database [Accessed April 30, 2017]

Abbvie started the most clinical trials, followed by GSK in second place.

Figure 3: top sponsors for industry-sponsored clinical trials initiated in Q1 2017

Source: GlobalData, Pharma Intelligence Center, Clinical Trials Database [Accessed April 30, 2017]